(APH.L) Alliance Pharma PLC Buy/Sell

RNS Number : 8815I Alliance Pharma PLC 19 March 2010

For immediate release 19 March 2010 ALLIANCE PHARMA PLC ("Alliance" or the "Company")

CULS Conversion and Additional Listing

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 18 and 19 March 2010 it received conversion notices in respect of £700,000 nominal value of the Company's 8% Convertible Unsecured Loan Stock ("CULS"). Accordingly, the Company has allotted 3,333,330 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to admission of the Ordinary Shares to trading on AIM.

In addition, the Company was notified on 19 March 2010 of the exercise of options to acquire 185,682 Ordinary Shares.

Application has been made by Alliance for 3,519,012 Ordinary Shares to be admitted to trading on AIM, and it is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 25 March 2010.

Following the conversion of the CULS and the exercise of the options, Alliance will have 225,684,564 Ordinary Shares and £6,800,000 of CULS in issue.

For further information:

Alliance Pharma plc + 44 (0) 1249 466966

John Dawson, Chief Executive Richard Wright, Finance Director www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic / Jennie Spivey

Numis Securities Limited + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Brent Nabbs Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS The company news service from the London Stock Exchange

MSCLLFESVRIALII

RNS Number : 8185I Alliance Pharma PLC 18 March 2010

For Immediate Release 18 March 2009

ALLIANCE PHARMA PLC

Notification of Major Interests in Shares

1. Identity of the issuer or the underlying issuer Alliance Pharma plc

of existing shares to which voting rights are attached: 2. Reason for the notification(please tick the appropriate box or boxes):
An acquisition or disposal of voting rights YES

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify):
3. Full name of person(s) subject to the New City High Yield Fund Limited

notification obligation: 4. Full name of shareholder(s) (if different from 3.)
5. Date of the transaction and date on 16 March 2010

which the threshold is crossed or reached:
6. Date on which issuer notified: 17 March 2010
7. Threshold(s) that is/are crossed or Below 3%

reached:

8. Notified details: A: Voting rights attached to shares
Class/type of Situation previous Resulting situation after the triggering transaction
shares to the triggering
transaction

if possible using the ISIN CODE
Number Number Number Number of voting % of voting rights
of of of shares rights
Shares Voting
Rights
Direct Direct Indirect Direct Indirect
Ordinary Shares 600,000 600,000 150,000 Below 3%

B: Qualifying Financial Instruments Resulting situation after the triggering transaction
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion Period rights that may be rights
acquired if the
instrument is
exercised/ converted

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments Resulting situation after the triggering transaction
Type of financial Exercise price Expiration date Exercise/ Number of voting % of voting rights
instrument Conversion period rights instrument
refers to

Convertible Bond 31/12/2013 31/12/2013 6,303,358 Nominal Delta

Below 3%

Total (A+B+C)
Number of voting rights Percentage of voting rights
6,453,358 Below 3%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Proxy Voting:
10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease N/A

to hold:
12. Date on which proxy holder will cease to hold N/A

voting rights:

13. Additional information: Compliance Officer, New City Investment Managers
(FRN: 408091)
14. Contact name: Kate Haswell
15. Contact telephone number: 020 7201 6900

This information is provided by RNS The company news service from the London Stock Exchange

HOLLLFVEVLITLII

RNS Number : 7100I Alliance Pharma PLC 17 March 2010

For immediate release 17 March 2010 ALLIANCE PHARMA PLC ("Alliance" or the "Company")

Transfer of distribution agreement

In the announcement on 8 February 2010 concerning the acquisition of 18 prescription products from Cambridge Laboratories (Ireland) Limited and Cambridge Laboratories Limited (together the "Vendors"), it was noted that timing of the transfer of one of the products from the Vendors to Alliance was dependent on the related distribution contract (the "Distribution Agreement") being executed. This related to the appointment by Biovail Laboratories International (Barbados) SRL of one of the Vendors as the distributor in the United Kingdom and the Republic of Ireland of tetrabenazine, which is marketed under the brand names Xenazine® in the United Kingdom and NitomanTM in the Republic of Ireland.

The Company is pleased to announce that the Distribution Agreement has now been executed and the benefit transferred to Alliance on 16 March 2010. As a consequence, £1.5m of deferred consideration will now be paid to the Vendors.

Xenazine® and NitomanTM are approved for use in the United Kingdom and the Republic of Ireland in connection with chorea associated with Huntington's Disease, tardive dyskinesia and certain other indications. The Distribution Agreement also conditionally provides for Alliance to be appointed as distributor of new formulations of tetrabenazine that are developed, including, potentially, a modified-release formulation that is currently in development for Tourette's Syndrome in 5-16 year old children.

For further information:

Alliance Pharma plc + 44 (0) 1249 466966

John Dawson, Chief Executive Richard Wright, Finance Director www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic / Jennie Spivey

Numis Securities Limited + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Brent Nabbs Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS The company news service from the London Stock Exchange

AGRUBAVRRKAOARR

RNS Number : 5723I Alliance Pharma PLC 15 March 2010

For immediate release 15 March 2010 ALLIANCE PHARMA PLC ("the Company")

Major Interest in Shares

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was informed on 15 March 2010 that Nigel Wray purchased, on 12 March 2010, 200,000 ordinary shares of 1p each in the Company.

Mr Wray's resultant shareholding is 24,519,995 ordinary shares, equivalent to 11.04% of the Company's issued share capital.

Mr Wray's ordinary shares are held as follows:

Nominee Number of ordinary shares

Pershing Keen Nominees Limited 8,905,407
Smith & Williamson Nominees Limited 50,000
Roy Nominees Limited 15,564,588

For further information:

Alliance Pharma plc + 44 (0) 1249 466966

John Dawson, Chief Executive Richard Wright, Finance Director www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic / Jennie Spivey

Numis Securities Limited + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Brent Nabbs Corporate Broking: David Poutney

This information is provided by RNS The company news service from the London Stock Exchange

HOLSFLFSIFSSEDD